Pharmaceuticals, Biotechnology and Life Sciences
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)…
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – – IVX-A12 was…
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loanCHASKA, Minn.,…
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development…
The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the AppointmentRESEARCH TRIANGLE PARK, N.C., May…
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company…
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX),…
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million…
TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with…
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are expected in…